Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change $ Change
grade C $35.65 2.35% 0.82
ACAD closed up 2.35 percent on Monday, March 27, 2017, on 58 percent of normal volume.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical ACAD trend table...

Date Alert Name Type % Chg
Mar 27 Stochastic Buy Signal Bullish 0.00%
Mar 27 Bollinger Band Squeeze Range Contraction 0.00%
Mar 23 NR7 Range Contraction 3.48%
Mar 23 Stochastic Reached Oversold Other 3.48%
Mar 23 180 Bearish Setup Bearish Swing Setup 3.48%
Mar 22 Doji - Bullish? Reversal 2.06%
Mar 22 Lizard Bullish Bullish Day Trade Setup 2.06%
Mar 22 Lower Bollinger Band Walk Other 2.06%
Mar 21 Fell Below 50 DMA Bearish 1.83%
Mar 21 Expansion Pivot Sell Setup Bearish Swing Setup 1.83%

Older signals for ACAD ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer’s disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson’s disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Is ACAD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 42.49
52 Week Low 20.68
Average Volume 2,015,255
200-Day Moving Average 32.068
50-Day Moving Average 35.953
20-Day Moving Average 36.508
10-Day Moving Average 36.242
Average True Range 1.2798
ADX 22.3
+DI 17.71
-DI: 23.54
Chandelier Exit (Long, 3 ATRs) 36.2506
Chandelier Exit (Short, 3 ATRs) 37.6894
Upper Bollinger Band 38.6384
Lower Bollinger Band 34.3776
Percent B (%b) 0.3
Bandwidth 0.116709